rifampin has been researched along with glasdegib* in 1 studies
1 trial(s) available for rifampin and glasdegib
| Article | Year |
|---|---|
Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
This study aimed to evaluate the effect of a strong CYP3A inducer, rifampin, on glasdegib pharmacokinetics in healthy volunteers.. In an open-label, fixed-sequence, two-period Phase 1 study, subjects received a single 100-mg oral dose of glasdegib alone or following once-daily pre-treatment with 600 mg rifampin. Glasdegib pharmacokinetics were calculated using a noncompartmental analysis.. Twelve healthy male volunteers (3 whites, 5 blacks and 4 others) were enrolled in the study. Mean age, weight, height and body mass index was 37.8 years, 83.0 kg, 177.3 cm and 26.5 kg (m. Co-administration of rifampin expectedly decreased glasdegib AUC Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzimidazoles; Connecticut; Cytochrome P-450 CYP3A Inducers; Drug Administration Schedule; Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Phenylurea Compounds; Rifampin; Risk Factors; Smoothened Receptor; Young Adult | 2018 |